首页> 外文期刊>Bulletin of Emergency and Trauma >Biomarkers in Shock Patients and Their Value as A Prognostic Tool; A Prospective Multi-Center Cohort Study
【24h】

Biomarkers in Shock Patients and Their Value as A Prognostic Tool; A Prospective Multi-Center Cohort Study

机译:休克患者的生物标志物及其作为预后工具的价值;前瞻性多中心队列研究

获取原文
           

摘要

Objective: To investigate the prognostic value of clinical and laboratory tests in prediction of outcome in patients at day 30 post presentation to hospital with shock and to determine the prognostic value of mid regional pro-adrenomedullin (MR-proADM) on mortality prediction at 30 days in the same patient cohort.Method: This prospective multicenter cohort study analyzed data from patients who had presenting with shock to the emergency departments of eleven urban, tertiary-care University hospitals in Spain between March, 2011 and May, 2011. Recruitment of patients was via convenience sampling. Inclusion criteria included age between 14 and 100 years with clinical diagnostic criteria of shock on admission. Various patient parameters were analysed, such as age, sex, past medical history. Other clinical variables were measured on arrival to hospital, including sequential organ failure assessment score (score SOFA), blood pressure, oxygen saturations, capillary refill time and shock index (SI). Laboratory variables investigated included base excess, MR-proADM, lactate, C-Reactive Protein (CRP) and procalcitonin (PCT).Results: There were 212 patients included in the study from the eleven hospitals involved. The mean age was 72.2 years old and 60.4% of the patients were men. In the discriminant analysis only age, MR-proADM and PCT remained in the final discriminant equation. The separate analysis of MR-proADM showed that, in the non-survivors group, MR-proADM levels are significantly higher than those found in the group of survivors (p0.001).Conclusion: Age, PCT and MR-proADM were useful to predict short-term mortality in patients presenting to the emergency department shock. This suggests that PCT and MR-proADM in combination with the most common prediction models will improve prognostic value.
机译:目的:探讨临床和实验室测试对休克出院后30天患者预后的预测价值,并确定中位区域肾上腺髓质素(MR-proADM)对30天死亡率预测的预后价值方法:这项前瞻性多中心队列研究分析了2011年3月至2011年5月之间西班牙11所城市,三级医疗大学医院急诊室中出现休克症状的患者的数据。通过方便抽样。纳入标准包括年龄在14至100岁之间,以及入院时电击的临床诊断标准。分析了各种患者参数,例如年龄,性别,既往病史。其他临床变量在到达医院后进行了测量,包括连续器官衰竭评估评分(SOFA评分),血压,血氧饱和度,毛细血管充盈时间和休克指数(SI)。研究的实验室变量包括碱超标,MR-proADM,乳酸盐,C反应蛋白(CRP)和降钙素(PCT)。结果:参与研究的11家医院共有212名患者。平均年龄为72.2岁,其中60.4%为男性。在判别分析中,仅年龄,MR-proADM和PCT保留在最终判别方程中。 MR-proADM的单独分析表明,在非幸存者组中,MR-proADM水平显着高于幸存者组(p <0.001)。结论:年龄,PCT和MR-proADM对预测出现在急诊室休克的患者的短期死亡率。这表明PCT和MR-proADM与最常见的预测模型结合将改善预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号